P24, a glycogen synthase kinase 3 (GSK 3) inhibitor  by Pérez Martı́n, Concepción et al.
P24, a glycogen synthase kinase 3 (GSK 3) inhibitor
Concepcio¤n Pe¤rez Mart|¤n 1, Jesu¤s Va¤zquez, Jesu¤s Avila, Francisco J. Moreno *
Centro de Biolog|¤a Molecular ‘Severo Ochoa’, Universidad Auto¤noma de Madrid, Cantoblanco, 28049 Madrid, Spain
Received 22 February 2001; received in revised form 8 October 2001; accepted 19 October 2001
Abstract
A heat resistant glycogen synthase kinase 3 (GSK 3) binding protein, p24, that inhibits its kinase activity at a low
magnesium concentration (in a way similar to that of lithium) was found in microtubules from adult rat brains. This protein
associates with GSK 3 in microtubules and corresponds to one previously described in the literature as p25, although it has a
relative molecular weight of 23 472. p24 is a poor substrate for GSK 3 but it could be phosphorylated by other protein
kinases such as cAMP dependent protein kinase and cdk 5. Since p24 could form complexes with GSK 3, it may not only
regulate GSK 3 activity but also it might act as an anchoring protein for the kinase. ß 2002 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Glycogen synthase kinase 3 (GSK 3) is a serine/
threonine kinase that was ¢rst described by its ability
to phosphorylate glycogen synthase and therefore
control glycogen metabolism. However, additional
roles for GSK 3 in cell growth and development
have been indicated [1,2]. Furthermore, GSK 3
may also be involved in Alzheimer’s disease (AD)
[3] through the phosphorylation of microtubule asso-
ciated tau [4] by the kinase [5]. Hyperphosphorylated
tau is the main component of neuro¢brillary tangles
[6] that are found in brains of AD patients [7].
GSK 3 is expressed as a single isoform in inverte-
brates but in vertebrates two isoforms have been de-
scribed [8]. The activity of GSK 3 can be regulated
through its interaction with proteins such as GSK 3
binding protein (GBP) [9], FRAT1 [10], and axin
[11].
GSK 3 is also known as tau protein kinase 1
(TPK1), since it phosphorylates tau protein [5].
GSK 3 has been isolated from brain microtubules
[12]. We have isolated GSK 3 from newborn and
adult rat brain microtubules and have detected a
protein with an electrophoretic mobility correspond-
ing to 24 kDa that copuri¢es with GSK 3. This pro-
tein is present in the microtubule fraction from adult
rat brain but not from newborn rat brain. We report
the isolation and characterization of this novel GBP,
which has previously been identi¢ed by other authors
[13,14]. We have studied the phosphorylation of p24
by GSK 3 and other kinases and discuss the conse-
quences of this phosphorylation in a similar region to
that found in the protein tau [13,14].
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2. Materials and methods
2.1. Materials
[Q-32P]ATP was purchased from Amersham.
Mouse monoclonal antibody to GSK 3L/TPK1 was
purchased from Transduction Laboratories (Lexing-
ton, KY, USA). ATP was purchased from Boehr-
inger-Mannheim. DEAE-cellulose and phosphocellu-
lose were from Whatman. The recombinant GSK 3L,
containing histidine tails (catalog number G 1663),
and the catalytic subunit of cAMP dependent protein
kinase (PKA, P 2645) were purchased from Sigma
(St. Louis, MO, USA). According to the supplier’s
speci¢cations, the kinases were puri¢ed to greater
than 90% homogeneity from Escherichia coli and
from bovine heart to a speci¢c activity of 30 and
50 U/Wg protein, respectively. The activity of GSK
3L using glycogen synthase 1 (GS-1) as substrate was
175 pmol/min/Wg protein. The activity of PKA using
p24 as substrate was 20 pmol/min/Wg protein. Phen-
ylmethylsulfonyl £uoride (PMSF), benzamidine,
EDTA, EGTA, heparin-acrylic beads, MES and
Tris were obtained from Sigma. Alkaline phospha-
tase was obtained from Roche (catalog number
713023, Germany).
Brains were isolated from Wistar rats or mice of
di¡erent ages and homogenized in bu¡ers containing
0.32 M sucrose, 10 mM phosphate pH 7.0, 1 mM
MgCl2, 2 mM EGTA, 1 mM PMSF and 1 mM
benzamidine. Homogenates were centrifuged at
100 000Ug for 1 h at 4‡C. The supernatants (brain
cytosolic fractions) were collected. Subsequently p24
was puri¢ed from rat brain microtubules [13] follow-
ing in part the procedure described by Woodgett [8]
for GSK 3L including an extra boiling step, to sep-
arate GSK 3 from p24. The protein in bu¡er 10 mM
Tris^HCl pH 7.4, 1 mM EGTA and 15 mM 2-mer-
captoethanol (bu¡er A) was heated at 100‡C for 20
min. Denatured proteins were removed by centrifu-
gation and the supernatant was chromatographed on
DEAE-cellulose. The £ow-through fractions in bu¡er
A were applied to a heparin-acrylic column. p24 was
eluted with a gradient of 100^500 mM NaCl. Frac-
tions containing p24 were dialyzed against bu¡er A
and chromatographed on S-Sepharose by eluting
with bu¡er A+250 mM NaCl. The p24 fractions
were diluted two-fold and applied to ATP-agarose.
After washing with bu¡er A+125 mM NaCl, p24 was
eluted with 0.125^1 M NaCl. p24 fractions were con-
centrated by ammonium sulfate precipitation and di-
alyzed against bu¡er A containing 30% glycerol and
stored at 320‡C [8]. About 0.4 Wg was obtained from
1 mg of initial protein (brain homogenate soluble
protein). Cdk 5 and PKC were puri¢ed from rat
brain as indicated by Takahashi et al. [13] and Yo-
kozeki et al. [14], respectively.
The glycogen synthase peptides (GS-1/GS-1-P)
YRRAAVPPSPSLSRHSSPHQS*EDEE containing
serine 21 in phosphorylated or unphosphorylated
form were synthesized on an automatic solid phase
peptide synthesizer (type 430A, Applied Biosystems)
and puri¢ed by reverse phase HPLC on a NovaPak
C18 column. The glycogen synthase peptide contain-
ing phosphoserine 21 is a good substrate for GSK 3,
whereas the same peptide containing unmodi¢ed ser-
ine is a poor substrate for the enzyme [15].
Recombinant stathmin [16] was puri¢ed from E.
coli transformed with bacterial expression plasmids
encoding wild-type stathmin. Extraction and puri¢-
cation of recombinant stathmin was performed as
follows: 2 h after induction by isopropyl thio-L-D-
galactoside, the cells were pelleted by centrifugation
at 4‡C and resuspended in bu¡er A, with 1 mM
benzamidine and 1 mM PMSF. The cell suspension
was sonicated ¢ve times for 60 s at 0‡C, and dis-
rupted cells were centrifuged at 4‡C. The supernatant
was puri¢ed as described by Belmont and Mitchin-
son [17] with some modi¢cations. As an additional
step in the puri¢cation, proteins were chroma-
tographed on DEAE-cellulose, before the HPLC
step.
2.2. Electrophoresis
SDS^PAGE was carried out by the procedure of
Laemmli on 8%, 10% or 15% polyacrylamide gels
[18]. Gels were either stained with Coomassie bril-
liant blue or subjected to Western blot analysis (see
below). Densitometric analysis was performed on dif-
ferent Western blot samples and the data processed
with an imaging densitometer (GS-6470 model, Bio-
Rad). Data were analyzed with Molecular Analyst
software.
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2.3. Antibodies and analysis by Western blots
Polyclonal antibodies against p24 were raised in
rabbit by successive injections of 0.2 mg puri¢ed pro-
tein. The speci¢c reaction of antibody against p24
was checked by dot-blot Western blot and competi-
tion assays as indicated by Ulloa et al. [19]. A stan-
dard curve to determine the reaction of the antibody
with increasing amounts of p24 was performed.
To test for the interaction of p24 with GSK 3L, we
employed a non-denaturing PAGE system. Accord-
ingly, puri¢ed p24 (0.125 Wg) was mixed with GSK
3L (0.015 Wg) in bu¡er 50 mM Tris^HCl pH 7.5
containing 10 mM MgCl2. The mixture was incu-
bated at 37‡C for 30 min to allow p24 binding to
GSK 3L. At the end of incubation running 40 mM
Tris^HCl, 200 mM glycine and 24 mM EDTA bu¡er
(TGE bu¡er) was added and then loaded on to a 6%
polyacrylamide gel and run at 100 V for 2 h. At the
end of the run, the gels were electrotransferred to
nitrocellulose ¢lters to detect the mobility for p24,
GSK 3 and the possible complex between both pro-
teins.
Also, to test for the interaction of p24 with GSK
3L, a co-immunoprecipitation analysis was carried
out. Soluble protein from newborn and adult mouse
brain homogenates were mixed with antibody raised
against p24 protein and, afterwards, with protein A
Sepharose (Transduction Laboratories, catalog num-
ber P40041). The pelleted protein (after low speed
centrifugation) was characterized by electrophoresis
and Western blot using antibodies raised against
GSK 3L and p24. In some experiments, to avoid
overlapping of GSK 3L and p24 with immunoglob-
ulin subunits, the electrophoresis was carried out
under non-denaturing conditions. Finally, to further
test the interaction of p24 with GSK 3L, a GSK 3L
containing histidine tails (which binds to nickel
beads) was used. p24 binding to nickel beads in the
presence or absence of that type of histidine-GSK 3
was tested.
2.4. Enzymatic assays
GSK 3 assays were carried out as previously de-
scribed [20]. It was also done at di¡erent Mg2 con-
centrations (1^10 mM). Our results indicated that a
similar activity was found at 3.3 and 10 mM Mg2
whereas at 1 mM Mg2 activity was less than 40% of
that seen with 3.3 mM Mg2. The phosphorylation
of stathmin by PKA was performed as previously
described by Moreno et al. [21]. Phosphorylation
by PKC was measured as described by Correas et
al. [22]. Phosphorylation by cdk 5 was assayed as
described by Takahashi et al. [13]. Alkaline phospha-
tase treatment was done as described by Ulloa et al.
[19]
2.5. ‘In gel’ digestion of proteins, extraction of
peptides and analysis by mass spectrometry
SDS^PAGE gels were stained with Coomassie
blue, and the bands of interest excised and subjected
to in situ digestion with trypsin as described Svechen-
ko et al. [23]. Gel extracts were pooled, dried down,
resuspended in 10 Wl of 0.1% tri£uoroacetic acid and
subjected to an automated desalting procedure [24]
with slight modi¢cation. Brie£y, the resuspended ex-
tracts were injected onto a RP-HPLC nanocolumn
(Vydac C18, 300 Wm i.d.) at a £ow of 3^5 Wl/min
using a Smart HPLC instrument with automatic
fraction collection (Pharmacia Biotech, Uppsala,
Sweden) equipped with a £owsplitter and working
at about 100 Wl/min. Peptides were eluted in a single
step with methanol/water (7:3) containing 0.1% for-
mic acid, and fractions of about 5 Wl were collected.
The fraction containing the peptide pool was used
for mass spectrometry analysis, using an ion trap
mass spectrometer model LCQ (Finnigan, Thermo-
Quest, San Jose, CA, USA) equipped with a nano-
spray interface, as described previously [25]. MS/MS
spectra from selected peptides were used for database
search using Sequest program (Finnigan Thermo-
Quest), in the comprehensive non-redundant protein
sequence database nr.FASTA (NCBI Resources,
NIH, Bethesda, MD, USA).
2.6. EDC cross-linking
Puri¢ed p24 (0.48 mg/ml) was incubated in 50 mM
Tris^HCl pH 7.4, 1 mM EGTA, 1 mM EDTA,
10 mM MgCl2 and cross-linked with freshly prepared
1 mM 1-ethyl-3-(3-dimethyl-aminopropyl)carbodi-
imide (EDC) in the dark [26]. The reaction was
stopped after 30 min by the addition of glycine and
2-mercaptoethanol at ¢nal concentrations of 50 mM
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and 10%, respectively, and the cross-linked proteins
characterized by gel electrophoresis and Western blot.
3. Results
3.1. Presence of a 24 kDa protein in adult rat brain
microtubule fraction
Since GSK 3 has been shown to be associated with
microtubules [5], microtubules were isolated by in
vitro polymerization as the ¢rst puri¢cation step
for the kinase. Since one of the GSK 3 isoforms
(GSK 3L) is developmentally regulated in brain [27]
microtubules were obtained from newborn and adult
(6 month) rat brain extracts. Since di¡erences in the
composition of the high molecular weight microtu-
bule associated proteins (MAPs) have been exten-
sively described before [28], we focused on di¡erences
in the low molecular weight MAPs. We observed a
protein with an electrophoretic mobility correspond-
ing to p24 kDa in the MAP fraction only from adult
rat brain (Fig. 1). A decrease in the amount of GSK
3 (49%) in adult brain microtubules was also ob-
served compared to that of newborn brain microtu-
bules (as determined by Western blot analysis). To
compare the relative amounts of p24 protein, a West-
ern blot analysis was carried out by testing samples
from di¡erent brain developmental stages together
with a known amount of puri¢ed p24. From the
data of Fig. 1C we calculate that in a 21 day old
rat there is 0.4 Wg of p24/mg total protein.
3.2. Puri¢cation and characterization of the p24
protein
Based on our initial observation that p24 is a heat
resistant protein, we performed, on isolated micro-
tubule protein, a preliminary puri¢cation step involv-
ing heat denaturation (see Section 2). Subsequently,
chromatography with DEAE-cellulose, heparin-
acrylic and ATP-agarose were performed to yield
an essentially homogeneous protein (Fig. 2A).
In order to identify p24, it was separated by SDS^
PAGE, subjected to ‘in gel’ digestion with trypsin,
and the resulting peptides analyzed by nanospray
ion trap mass spectrometry as described in Section
2. Two of the peptides produced clear MS/MS spec-
Fig. 1. p24 protein is present in adult rat brain microtubules.
(A) Microtubules were isolated in vitro from newborn (NB) or
adult (A) brain rat and the microtubule protein was fractionat-
ed by gel electrophoresis. The electrophoretic mobilities for tu-
bulin (tb) and for a protein with an electrophoretic mobility
corresponding to 24 kDa (p24) are indicated. In the center lane
the mobility for puri¢ed p24 is indicated (see text). (B) GSK 3
activities tested on GS-1 peptide (see Section 2) from newborn
(NB) or adult (A) rats are indicated. The activity for enzyme
from newborn rats was set at 100%. (C) Determination of GSK
3 and p24 levels by Western blot using GSK 3 and p24 anti-
bodies, in newborn animals (1), 1 week old (2), 2 weeks old (3),
3 weeks old (4), 5 weeks old (5), 2 months old (6), 4 months
old (7), 6 months old (8), and 10 months old (9), in each lane
10 Wg of protein was loaded. In lane M is indicated the reac-
tion of p24 antibody with 0.05 Wg of puri¢ed p24.
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tra (Fig. 2B), which were used for database search-
ing. These two peptides, VDLVDESGYVPGYK and
TITFEQFK, were positively identi¢ed. These pep-
tides corresponded to a protein of 25 kDa previously
described [29] and known as p25. Since ‘p25’ is also
used to refer to another protein that interacts with
tau protein kinase II (cdk 5), a kinase that also modi-
¢es tau protein [30], we will henceforth continue to
refer to the protein of this study as p24 (since this
corresponds to its molecular weight as determined by
its amino acid composition [29].
Further characterization of p24 by gel ¢ltration
(not shown) indicated that it could behave as a
dimer. To test this hypothesis experiments using
EDC as crosslinker were performed. Fig. 3 shows
that p24 could form dimers as determined by gel
electrophoresis. At higher EDC concentrations larger
protein aggregates were also observed at the top of
the gel (not shown).
Fig. 2. p24 protein puri¢cation and sequencing. (A) p24 was isolated from an adult brain microtubule preparation through di¡erent
puri¢cation steps: heat treatment and DEAE-cellulose, heparin-acrylic and ATP-agarose chromatographies. A protein puri¢ed almost
to homogeneity was isolated. (B) Identi¢cation by mass spectrometry of one tryptic peptide from p24. The band corresponding to p24
was digested with trypsin, the extracted peptide pool subjected to microdesalting and analyzed by nanospray ion trap mass spectrome-
try. Shown is the MS/MS spectrum obtained from one of the peptides. The spectrum was subjected to database searching using Se-
quest software, and a clear match was found with the sequence depicted. The identity of the fragment peaks has been assigned in the
spectrum using the nomenclature of [38].
Fig. 3. p24 could form dimers. Puri¢ed p24 (0.48 mg/ml) was
incubated in the presence of 1 mM EDC for 10 and 20 min at
37‡C. The treated protein was fractionated by gel electrophore-
sis. The electrophoretic mobilities for p24, p24 dimers and mo-
lecular weight markers is shown. (a) p24 in the absence of
EDC; (b) p24 after 10 min incubation in the presence of EDC;
(c) p24 after 20 min incubation in the presence of EDC.
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3.3. Binding of GSK 3 to p24
Since we used a microtubule associated fraction as
a source to obtain GSK 3 and p24 we tried to devel-
op a protocol to fractionate these proteins. However,
we observed that GSK 3 (measured by its activity)
copuri¢es with p24 (when the heat resistant step was
omitted) through DEAE-cellulose, heparin-acrylic
and ATP-agarose chromatographies. Contaminating
GSK 3 was undetectable by Coomassie blue staining
after gel electrophoresis, and its presence could only
be measured either by enzymatic activity or by West-
ern blot. We observed that puri¢ed recombinant
GSK 3 binds to puri¢ed p24 (free of GSK 3 after
the heat resistant step) as determined by native gel
electrophoresis followed by Western blot (Fig. 4A).
Di¡erent amounts of p24 from 0.01 to 3 Wg/10 Wl
Fig. 4. Binding of GSK 3 to p24. (A) Puri¢ed p24 (0.125 Wg in
10 Wl) was incubated in the absence (a) or in the presence of re-
combinant GSK 3 (0.015 Wg in 10 Wl) (aP) and incubated for 30
min at 37‡C. p24 (a) and the resulting complex (aP) were identi-
¢ed by native electrophoresis, in 6% acrylamide gels in the pres-
ence of TGE bu¡er by Western blot using an antibody raised
against p24. Additionally, the electrophoretic mobilities of GSK
3 (b) and that of the complex GSK 3^p24 (bP) were identi¢ed
by Western blot using an antibody raised against GSK 3. (B)
Co-immunoprecipitation analysis of newborn rat brain protein
(Po) and 6 month old rat brain protein (Pm) using an antibody
against p24 (+) or a preimmune serum (3). The Western blots
using GSK 3 antibody (to react with the immune precipitate
(P) or supernatant (SN) fractions) or p24 antibody are shown.
(C) Interaction of p24 with GSK 3 was mixed in the presence
(a) or absence (b) of 0.5 Wg of GSK 3 bearing histidine tails
and the protein bound to nickel beads was identi¢ed by its re-
action with both antibodies raised against p24 and GSK 3.
Fig. 5. Action of GSK 3 on p24. To test if p24 is a suitable
substrate for GSK 3, p24 (4 WM, about 0.08 mg/ml) was incu-
bated with GSK 3 (0.5 U, about 1.3 Wg/ml) in the presence of
increasing amounts of ATP. Phosphate incorporation (less than
0.01 mol phosphate/mol protein at 100 WM ATP) was measured
(R) (see right ordinate). In parallel the phosphate incorporation
into GS-1 peptide (15 WM) (8) was measured (see left ordinate)
yielding an incorporation of 1.5 mol of phosphate incorporated/
mol of GS-1 peptide at 100 WM ATP. (B) In a similar way to
that described in panel A the phosphorylation of p24 by PKA
and cdk 5 was determined at an ATP concentration of 100
WM.
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were mixed with a ¢xed amount of GSK 3 (0.02 Wg/
10 Wl) and native gel electrophoresis (followed by
western blot) was carried out to look for complex
formation. Our results indicate that 0.02 Wg of
GSK 3 and 0.05 Wg of p24 mixed in a ¢nal volume
of 10 Wl is the minimal amount required for complex
formation. It suggests that one molecule of GSK 3
could bind to around ¢ve molecules of p24. Since
p24 could form aggregates (F. Moreno, unpublished
observations) it is possible to suggest that GSK 3
mainly binds to p24 aggregates.
To further study the binding of GSK 3 to p24, co-
immunoprecipitation (using p24 antibody) was
tested. Fig. 4B shows that p24 is essentially absent
in newborn rat and, therefore, no GSK 3L was found
in the immunoprecipitate, whereas in mature rat
there is co-immunoprecipitation of p24 and GSK 3.
No immunoprecipitation was observed in either case
with a preimmune serum (Fig. 4B).
Additionally, the binding of p24 to GSK 3 was
measured by using a GSK 3 protein bearing histidine
tails (which binds to nickel beads) and by testing the
binding of p24 to those beads, in the presence or
absence of the previously indicated type of GSK 3
protein. The results in Fig. 4C support the hypoth-
esis that p24 forms complexes with GSK 3, since p24
only binds to nickel beads in the presence of GSK 3.
3.4. E¡ect of p24 on protein kinase activities
We tested if p24 is a substrate for GSK 3, and
found that it is a poor substrate for the kinase (see
Fig. 5). We next tested how p24 a¡ects GSK 3 ac-
tivity as measured by phosphorylation of a GS-1
peptide and the protein tau. Fig. 6 shows that in
the presence of p24 a decrease in kinase activity
was observed. As controls we tested the e¡ect of
p24 on other protein kinase activities. We found
that it has no e¡ect on PKC activity (not shown),
whereas it slightly increases PKA activity (measured
on stathmin as substrate). We also found that p24 is
a good substrate for PKA. In this case, an incorpo-
ration of 0.7 mol phosphate/mol p24 was found by
Fig. 6. E¡ect of p24 on kinase activities. The e¡ects of p24 ad-
dition on GSK 3 activity measured using GS-1 peptide (0.045
mg/ml or 15 WM) or tau (0.125 mg/ml) (the smallest central
nervous system isoform) as substrates (A) and on PKA activity
using stathmin as substrate (B) (a) in the absence of p24, (b) in
the presence of 0.08 mg/ml, (c) 0.24 mg/ml, (d) 0.48 mg/ml of
p24. The activities in the absence of protein (175 pmol/min/Wg
for GS-1, 8 pmol/min/Wg for tau and 50 pmol/min/Wg for stath-
min) were taken as 100%. ATP was used at 15 WM.
Fig. 7. E¡ect of phosphorylation of p24 on GSK 3 activity. (A)
Tau protein was phosphorylated in the absence (3) or presence
(+) of p24 unmodi¢ed (3) or previously phosphorylated by
PKA (+PKA) and its e¡ect on GSK 3 activity was measured
by gel electrophoresis followed by autoradiography to detect
the labeled phosphoprotein. (B) Tau protein was phosphorylat-
ed in the absence (a), or in the presence of 0.08 mg/ml (b), 0.24
mg/ml (c), or 0.48 mg/ml (d), of p24 unmodi¢ed (3) or previ-
ously treated with alkaline phosphatase (+AP). The electropho-
retic mobility for tau-P is indicated by an arrow.
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increasing ATP concentration, in a way similar to
that shown in Fig. 5. We also observed that p24 is
modi¢ed by cdk 5 (tau protein kinase II) yielding
about 0.9 mol phosphate incorporated per mol p24
(see also [13]).
Since p24 is a good substrate for PKA, we did the
phosphorylation of p24 with PKA under conditions
in which about one mol of phosphate was incorpo-
rated per mol of protein and we tested if that mod-
i¢cation a¡ects the inhibitory e¡ect of p24 on GSK
3L activity. Fig. 7 shows a decrease in this inhibitory
e¡ect when phospho-p24 was tested (Fig. 7A). On
the other hand, alkaline phosphatase treatment on
puri¢ed p24 did not a¡ect GSK 3 activity (Fig. 7B).
3.5. p24 inhibition of GSK 3 is dependent on
magnesium concentration
An inhibitory action of lithium of the speci¢c GSK
3 inhibitor has been found at low Mg2 concentra-
tions [31]. More recently it has been shown that lith-
ium is a competitive inhibitor of GSK 3 with respect
to Mg2, but not to substrate or ATP [32]. We tested
if a similar situation holds for the p24 inhibitory
e¡ect on GSK 3. Fig. 8 shows that the inhibitory
e¡ect of p24 on GSK 3 is indeed maximal at low
magnesium concentration (Fig. 8A), as observed
with LiCl (Fig. 8B). This result suggests a possible
common mechanism for p24 and LiCl for inhibition
of GSK 3.
4. Discussion
A novel GBP, p24, has been reported. Since this
protein binds to GSK 3 we tested if p24 can be
modi¢ed by the kinase or if GSK 3 activity can be
modi¢ed by p24. Even at very high concentrations of
GSK 3 phosphorylation of p24 is negligible and thus
probably has little physiological relevance since the
incorporation of mol phosphate per mol of protein is
below 0.01 at high ATP concentration.
Despite the fact that p24 is not a good substrate
for GSK 3, p24 protein can modify GSK 3 activity.
Thus, p24 could be considered a new GBP that reg-
ulates its activity (see [9]). The regulation of GSK 3
activity by p24 is suppressed at high magnesium con-
centration and it appears that p24 could, in same
way, mimic the action of lithium on GSK 3 [31,32],
since they shared this feature. Since lithium binds to
acidic residues of GSK 3, it should be further studied
if basic residues of p24 are also involved in the bind-
ing to GSK 3.
Another role for p24 could be to act as a sca¡old
protein, to which GSK 3 and possibly cdk 5 (see [13])
could bind, forming a complex similar to those of
other kinases bound to other sca¡old proteins
[33,34].
p24 can be modi¢ed by PKC (see [14]), and, as
shown in this work also by PKA and cdk 5 (or other
Fig. 8. E¡ect of magnesium on the inhibition of GSK 3 activity
by p24. (A) GSK 3 (0.5 U) was incubated with GS-1 (15 WM)
and ATP (15 WM) and decreasing concentrations of MgCl2
(10^1 mM) in the absence (a) or presence of 0.08 mg/ml (b) or
0.24 mg/ml of p24 (c), in a ¢nal volume of 12 Wl. The mixture
was incubated for 30 min at 37‡C and phosphate incorporation
was measured taking the value obtained in the absence of p24
(175 pmol/min/Wg) as 100% of activity. (B) The same experi-
ment indicated in panel A was performed but in this case p24
was replaced by increasing LiCl concentrations (up to 20 mM).
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cdks), and several substrate sequence motifs for these
kinases are present in p24 (see Fig. 9A). The cdk
target motif modi¢cation of a p24 sequence,
TPPKSP (12^17 amino acids in p24), is shared with
the MAP tau [13]. This sequence is phosphorylated
by cdk in tau [35] and it is a putative target for the
modi¢cation of p24 by that kinase [13].
p24 is expressed late in brain development [27]
whereas GSK 3L decreases its expression during de-
velopment [27]. Thus, a possible role for p24 could
be to increase the downregulation of remaining GSK
3 activity in late development. The presence of p24
could inhibit phosphorylation of tau and other cel-
lular substrates of GSK 3 (Fig. 9B,a). A further de-
crease in the phosphorylation of substrates, such as
tau, by GSK 3 may occur due to competition of
substrates since the sequence TPPKSP is present in
p24 [13] and the MAP tau (Fig. 9B,b). As a result of
such competition, further phosphorylation of tau by
GSK 3, which is promoted by its prior modi¢cation
by cdk proteins [36], will not take place. Thus, p24
could inhibit the phosphorylation of substrates such
as tau in at least two ways.
This competitive role of p24 and tau for common
proteins could be related to the onset of neuropatho-
logical disorders such as AD as explained in the fol-
lowing way (Fig. 9B,c). It is known that tau protein
can be phosphorylated by a cdk-type kinase at the
TPPKSP peptide thereby changing its conformation.
This conformational change could be reversed by
binding to Pin1, a chaperone protein, thus allowing
further dephosphorylation by PP2A [35,37], thus re-
covering microtubule binding activity. Thus, if in AD
there is an overexpression of kinases like cdc2 or
other cdk-type kinases, as previously proposed [35],
both tau and p24 could be phosphorylated and both
phosphorylated proteins could compete for a protein
like Pin1 (or PP2A), decreasing its activity and re-
sulting in an aberrant hyperphosphorylation of tau
protein, a feature that occurs in AD [6]. This possible
model for the action of p24 in the modi¢cation of
substrates like tau protein suggests that the presence
of p24 should result in a decrease in the modi¢cation
of proteins like tau by GSK 3, a point particularly
relevant for AD pathology. From our experiments
we can calculate a concentration of p24 in brain (if
uniform) of about 0.4 Wg/ml. This concentration is
probably below that needed for GSK 3 binding.
Thus, probably p24 should be more concentrated in
some brain region (or cells) to allow that interaction.
On the other hand, modi¢cation of p24 by phos-
phorylation or dephosphorylation may a¡ect its ef-
Fig. 9. (A) Consensus sites in p24 for modi¢cation by di¡erent
kinases. Putative phosphorylated residues in p24 molecule (p24
sequence is from [13]). The possible sites in p24 modi¢ed by
PKA (underlined) (consensus sequence RXXS/T), PKC (indi-
cated by +) (consensus sequence RXS) and cdk (indicated by ^)
(consensus sequence S/TP) are shown. (B) A model suggesting
how p24 could be implicated in the phosphorylation by GSK 3
of other substrates like tau: (a) by inhibition of kinase activity,
(b) by competition for the kinase with tau protein, since they
share a common sequence, (c) by competition between phos-
pho-tau and phospho-p24 for a protein like Pin1 which could
regulate their dephosphorylation.
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fect on GSK 3 activity. In this way our results in-
dicate that phosphorylation by PKA decreases the
e¡ect of p24 on GSK 3 activity whereas no e¡ect
on GSK 3 activity was observed for alkaline phos-
phatase treated p24 compared with that of untreated
p24. Then, changes in the level of phosphorylation of
p24 could also play a role in p24 function.
In summary, we have described a novel GBP that
could regulate the activity of this protein kinase and
could also act as a competitor for tau.
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